Corbus Pharmaceuticals Holdings Stock Prediction and Forecast [CRBP]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 29 Aug 2025, 03:10 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Corbus Pharmaceuticals Holdings Stock Prediction and Forecast [CRBP]](https://i.ytimg.com/vi/IIaWk7XkGIU/hqdefault.jpg)
AI-generated source summary
Corbus Pharmaceuticals Holdings, based on moving averages, presents a positive forecast. Short-term averages are above the long-term average. Downward corrections, support lies at $9.86 and $9.13. A breakdown of these values will issue sell signals. A buy signal from the 3-month Moving Average Convergence Divergence (MACD). Sell signal a pivot top on Wednesday, August 27, further fall is indicated until a new bottom pivot has been found. Volume fell along with the price, which is technically positive. CRBP stock has medium daily movements and medium risk. Short term: Buy long term: Sell. Trading levels with accumulated volume: Resistance at $10.47, Support at $8.67. Vitals : Risk is classified as medium and the weekly volatility is 6.84%. Insiders Buy 1938540 shares and sell 138404 shares. The analysis suggests a buy and expect CRBP to open higher by approximately $0.233 to start trading at $10.13.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
